Welcome to our dedicated page for Bruker news (Ticker: BRKRP), a resource for investors and traders seeking the latest updates and insights on Bruker stock.
News related to Bruker Corporation 6.375% Mandatory Convertible Preferred Stock (BRKRP) focuses on announcements from Bruker Corporation that affect this preferred equity and the broader business behind it. Bruker’s communications describe the company as enabling scientists and engineers to make post-genomic discoveries and develop applications that improve the quality of human life through high-performance scientific instruments and high-value analytical and diagnostic solutions.
For BRKRP, one key category of news is dividend announcements. Bruker has reported that its Board of Directors approved a quarterly cash dividend of $3.6745 per share on the 6.375% Mandatory Convertible Preferred Stock, Series A, which is identified as the Mandatory Convertible Preferred Stock Dividend. Such releases provide details on payment amounts and record dates that are important for holders of BRKRP.
Another category of news involves Bruker’s activity in diagnostics and advanced testing. For example, Bruker has been identified as the acquirer of AST Revolution, an in vitro diagnostics company focused on next-generation rapid antimicrobial susceptibility testing (AST) solutions. The transaction follows AST Revolution’s formation after acquiring select assets of Accelerate Diagnostics, including the WAVE and Arc systems and related intellectual property, which are intended to deliver rapid, actionable AST results for clinicians.
Visitors to this BRKRP news page can review dividend declarations affecting the preferred stock and corporate developments, such as acquisitions in diagnostics, that illustrate how Bruker is expanding or refining its scientific and analytical offerings. Monitoring these updates can help readers understand how Bruker’s strategic actions and capital decisions relate to the BRKRP preferred shares.
AST Revolution was announced as sold to Bruker (Nasdaq: BRKR, BRKRP) on November 24, 2025. Financial terms were not disclosed. AST Revolution launched in August 2025 after a court-approved acquisition of select assets of Accelerate Diagnostics under Chapter 11, and the deal includes the WAVE™ and Arc™ systems plus associated intellectual property. Indaba Capital, AST Revolution’s controlling sponsor, provided ongoing funding and operational support to rebuild the platform, advance product development, and position the business for this sale.
The company highlights continued scientific leadership under Chief Scientific Officer Lawrence Mertz and says Bruker is expected to be the long-term owner to commercialize the next-generation rapid antimicrobial susceptibility testing technologies.
Bruker (Nasdaq: BRKR, BRKRP) announced quarterly cash dividends for common and preferred shares.
The Board approved a $0.05 per share common stock dividend, payable January 2, 2026 to holders of record as of December 8, 2025. The Board also approved a $3.6745 per share dividend on the 6.375% Mandatory Convertible Preferred Stock, Series A, payable December 1, 2025 to holders of record as of November 15, 2025.
FAQ
What is the current stock price of Bruker (BRKRP)?
